Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Preventative Treatment for Migraine

NCT07279623 | Recruiting

• 2 other identifiers: A-MI-01CIV-25-05-052936
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical stimulation (INMEST), as a preventative treatment for migraine. A total of 110 adults (18-65 years) with a history of migraine will be randomized 1:1 into two groups: Group A (early treatment) and Group B (delayed treatment). The study includes baseline assessments, in-clinic device training, and home-based self-administered treatments every second day for six weeks. The primary outcome is the change in monthly migraine days during the primary treatment comparison period. Secondary outcomes include headache days, migraine intensity, duration, rescue medication use, patient-reported outcomes, device compliance, and safety. The study will be conducted at one site in Sweden.

Conditions

Migraine

Keywords

Migraine; Migraine prophylaxis / Preventive treatment; Neuromodulation; Intra-nasal mechanical stimulation; INMEST; Medical device; Chronic migraine; Episodic migraine; Headache disorders

Outcome Measures

Primary Outcomes (1)

• Change in Monthly Migraine Days

  Between-group comparison of the difference in mean change in monthly migraine days from the baseline assessment period (weeks 1-4) to Group A) Treatment performance period (weeks 7-10) and Group B) No treatment reference period (weeks 7-10).

  Weeks 7-10 (Group A: Treatment performance period; Group B: No treatment reference period)

Secondary Outcomes (29)

• Mean change in monthly headache days

  Weeks 7-10

• Mean change in migraine intensity

  Weeks 7-10

• Mean change in duration of migraine attacks

  Weeks 7-10

• Proportion of attacks requiring rescue medication

  Weeks 7-10

• Number of participants with ≥30% and ≥50% reduction in monthly migraine days

  Weeks 7-10

Other Outcomes (2)

• Device usability and user experience (combined questionnaires)

  Throughout the 6-week treatment period

• Symptom trends (Symptom Questionnaire)

  Throughout the 6-week treatment period

Study Arms (2)

Group A - Early Start

ACTIVE COMPARATOR

Subjects undergo a 4-week baseline assessment (weeks 1-4), then receive active treatment with the Walther System every second day for 6 weeks (weeks 5-10). The first treatment is performed under supervision at the clinic, and subsequent treatments are self-administered at home. Post-treatment assessments occur during weeks 11-14.

Device: INMEST-treatment

Group B - Delayed Start

ACTIVE COMPARATOR

Subjects undergo a 4-week baseline assessment (weeks 1-4), followed by a 6-week no-treatment reference period (weeks 5-10). Active treatment with the Walther System is then administered every second day for 6 weeks (weeks 11-16), starting with an initial supervised treatment at the clinic. Post-treatment assessments occur during weeks 17-20.

Device: INMEST-treatment

Interventions

INMEST-treatment DEVICE

Hand-held controller and catheter assembly for intra-nasal mechanical stimulation (INMEST), self-administered at home every second day for 6 weeks, first treatment under supervision.

Also known as: Walther System

Group A - Early Start; Group B - Delayed Start

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18-65 years at the time of screening.
• The study subject must have a clinical diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-3), indicated by medical record shown by the subject.
• Onset of migraine headache occurred before age 50.
• History of migraines for at least 1 year before screening.
• The study subject reports at least 8 monthly migraine days during the screening period.
• If subject is on a prophylactic migraine medication regimen:
• Reports stable medication regimen during the three months prior to screening.
• Able and willing to maintain medication regimen (no change in type, frequency or dose) from screening to end of follow-up.
• The study subject reports having understood and have signed the Informed Consent Form (ICF) and is willing to comply with all investigation visits and assessments.
• Women of childbearing potential must agree to use a reliable, medically approved form of contraception during the study participation until end of study.
• Anticipated compliance with prescribed treatment and follow-up.

You may not qualify if:

• Subject unable to distinguish between migraine headaches and other headache types.
• Recently (12 months prior screening) undergone nasal or sinus surgery.
• Any severe diseases for which, in the opinion of the Investigator, participation would not be in the best interest of the subject or that can interfere with the performance, evaluation, and outcome of the clinical evaluation.
• Previous (within 30 days prior to screening) and concurrent treatment with another investigational drug/s or device/s.
• Subject is pregnant or lactating or planning to get pregnant during the duration of the study.
• The study subject has a cognitive incapacity or language barrier precluding adequate understanding or cooperation.
• The study subject is considered by the Investigator to be unsuitable to participate in the investigation for any other reason.

Sponsors & Collaborators

• Abilion Medical Systems AB: lead
• Aurevia: collaborator
• Insamlingsstiftelsen för främjande av forskning avseende INMEST: collaborator

Study Sites (1)

INMEST-mottagningen Odenplan

Stockholm, 11327, Sweden

RECRUITING

MeSH Terms

Conditions

Migraine Disorders; Headache Disorders

Condition Hierarchy (Ancestors)

Headache Disorders, Primary; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Jan-Erik Juto, PhD, MD

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Karl-Johan Pantzar, MSc, MSc

CONTACT

+46(0)739808065; kj@abilion.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 18, 2025
• First Posted: December 12, 2025
• Study Start: October 21, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: December 12, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

SE (1)